Japan Lifeline (7575) Q1 2026 earnings summary

Executive summary

• Q1 FY2026 net sales rose 4.3% year-over-year to ¥14,616 million, with operating profit up 2.4% and net profit down 1.6% due to FX losses and asset disposals.

• Growth was driven by strong core product performance and expansion in new therapeutic areas, despite increased expenses, reimbursement price revisions, and negative pricing impacts.

• Business performance was in line with initial guidance, with segment gains in Cardiovascular, Neurovascular, and Gastrointestinal areas offsetting CRM and PFA-related declines.

• Sales volume increased, especially in AF procedures (+5-6% YoY), and new product launches contributed to segment growth.

Financial highlights

• Gross profit margin declined to 60% from 61.3% year-over-year, mainly due to price revisions and a lower proprietary sales mix.

• Operating profit margin decreased slightly to 22.4% from 22.8% year-over-year.

• Earnings per share rose to ¥32.85, up ¥0.90 year-over-year, aided by a share buyback.

• International sales mix increased to 2.4%, up 40 basis points year-over-year.

• Proprietary product sales fell 0.5% year-over-year, while procured product sales rose 10.8% year-over-year.

Outlook and guidance

• Q1 sales, operating profit, and net profit achieved 24.6%, 25.4%, and 24.6% of full-year guidance, respectively, indicating progress in line with expectations.

• Medium-term plan targets consolidated sales of ¥70 billion by March 2028, with new performance-linked stock options tied to this goal.

• Full-year forecast for FY ending March 31, 2026, remains unchanged: net sales ¥59,300 million (+4.8% YoY), operating profit ¥12,900 million (+4.7%), net income ¥9,350 million (+0.3%), and EPS ¥133.30.